No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CGEN240621C2000
- 0.15
- +0.09+150.00%
15min DelayClose Jun 14 15:55 ET
0.20High0.15Low
0.20Open0.06Pre Close31 Volume673 Open Interest2.00Strike Price470.00Turnover109.20%IV3.86%PremiumJun 21, 2024Expiry Date0.07Intrinsic Value100Multiplier5DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.6280Delta1.3405Gamma13.80Leverage Ratio-0.0100Theta0.0002Rho8.67Eff Leverage0.0010Vega
Intraday
- 5D
- 1D
News
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Express News | Compugen To Receive $5M Milestone Payment From AstraZeneca Following Dosing Of First Patient In Second Phase 3 Trial Of Rilvegostomig
Compugen Is Maintained at Buy by Truist Securities
Compugen Is Maintained at Buy by Truist Securities
Express News | Truist Securities Maintains Buy on Compugen, Lowers Price Target to $4
Compugen Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 118.58% Truist Securities $5 → $4 Maintains Buy 03/08/2024 173.22% Truist Securities $4 → $5 Ma
Express News | Compugen Ltd : Truist Securities Cuts Target Price to $4 From $5
Comments
$Compugen(CGEN.US$ 🤩
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
The market anticipates a decline in future revenue, possibly explaining the suppressed P/S. This weak revenue outlook could continue to pressure shares, making it hard to maintain current prices. Shareholders accept the low P/S, expecting future revenue may not bring pleasant surprises.
$Compugen(CGEN.US$ fk entered very early! now no option to hold at lesast 2 week or more !
$Compugen(CGEN.US$ 👀looks good i n game 🎲
Michelle Mahler's appointment as Chief Medical Officer is a positive step for Compugen, thanks to her vast clinical development experience. Her leadership in the COM503 Phase 1 study and future role in advancing COM701, COM902, and COM503 are anticipated to significantly boost the company's clinical development strategy.
Read more